PPARG and Alzheimer disease: Second, Michael Heneka (Bonn, Germany) described PPARγ as a mediator of protection in AD, and third, Anne Murphy (La Jolla, USA) dealt with the value of a preclinical systematic review to analyze mitochondria as targets of thiazolidinediones.